Bipolar disorder treatment for Miami — the diagnosis primary care misses.

RECO Integrated Psychiatry is 65 minutes north of Brickell on I-95, and the Miami clients who make the drive are typically the ones whose bipolar depression has been misdiagnosed as unipolar for years. The practice runs lithium, lamotrigine, valproate, and second-generation antipsychotic protocols with monitoring built in, not tacked on. Diagnosis uses MDQ, HCL-32, mood charting, and collateral history — not a fifteen-minute checklist — and telepsychiatry follow-ups keep the trip to Delray Beach infrequent once a regimen is stable.

For clients in Brickell, Coral Gables, and Coconut Grove, the drive north on I-95 to RECO Integrated Psychiatry’s Delray Beach office runs about 65 minutes in standard traffic — sixty-five minutes that most Miami psychiatrists do not ask their bipolar patients to travel, and sixty-five minutes that changes what a specialist visit looks like. Bipolar disorder is diagnosed correctly, on average, roughly ten years after symptoms begin, and that delay accounts for most treatment failures in this population. The Miami clients who make the trip are usually the ones whose antidepressant made them worse, whose sleep collapses cyclically, or whose primary care physician has run out of SSRIs to try.

Bipolar I, bipolar II, and bipolar spectrum

Bipolar I is defined by a full manic episode — seven days of elevated or irritable mood with functional impairment, psychosis, or hospitalization. Bipolar II requires a hypomanic episode of at least four days plus a documented major depressive episode; the hypomania is real but subthreshold for the disruption that defines mania. Bipolar spectrum presentations — BP-NOS, cyclothymia, and antidepressant-induced hypomania — carry clear cyclicity and family history but do not cleanly meet DSM-5 criteria.

The distinction is load-bearing because it dictates pharmacology. Bipolar I responds best to combinations of mood stabilizers and second-generation antipsychotics, particularly for acute mania and maintenance. Bipolar II depression, the pole where most of these patients spend the majority of their symptomatic time, responds well to lamotrigine and quetiapine but has a weaker signal with lithium monotherapy. Bipolar spectrum patients need mood stabilizer cover before any antidepressant trial to prevent iatrogenic destabilization.

RECO’s diagnostic workup uses the Mood Disorder Questionnaire (MDQ), the Hypomania Checklist-32 (HCL-32), structured mood charting across at least two weeks when possible, and collateral history from a partner or family member. First-degree family history of bipolar disorder, postpartum psychosis, or lithium-responsive depression each shift the pretest probability. The evaluation exists to catch the patients whose unipolar diagnosis is wrong.

Lithium: the treatment we take seriously when others don’t

Lithium is the mood stabilizer with the strongest long-term maintenance evidence and the only psychiatric medication with a documented anti-suicide effect independent of its mood-stabilizing action. Aggregate data show roughly a 60% reduction in suicide attempts and completions in bipolar patients on lithium versus alternatives. It remains, by any measured outcome, the first-line maintenance agent for classic bipolar I.

The reason it is underused is monitoring. Lithium requires baseline TSH, creatinine, calcium, CBC, and a pregnancy test where relevant. Maintenance targets are 0.6-1.0 mEq/L drawn twelve hours post-dose, quarterly for the first year and then twice yearly if stable. Thyroid, renal function, and calcium are retested annually. Patients need counseling on hydration, NSAIDs, and sodium — dehydration or a week of ibuprofen can push a therapeutic level into toxicity.

RECO’s protocol builds the monitoring in rather than treating it as an obstacle. For clients who tolerate lithium — and most do at 600-900 mg extended-release nightly — the outcomes justify the labs. Tremor, weight gain, and thyroid risk are real; they are also manageable, and they are not reasons to default to a weaker agent.

Second-generation antipsychotics and where they fit

Multiple second-generation antipsychotics carry FDA approval in specific bipolar indications, and phase drives selection more than habit does. Quetiapine covers bipolar depression, acute mania, and maintenance — one of the few agents indicated across all three phases. Lurasidone is approved for bipolar depression with a favorable metabolic profile. Aripiprazole and cariprazine treat mania and provide maintenance; olanzapine and the olanzapine-fluoxetine combination address bipolar depression and mania at the cost of significant weight and metabolic burden. Risperidone is approved for acute mania.

Metabolic monitoring is standard: baseline and periodic weight, waist circumference, fasting glucose or HbA1c, lipid panel, and blood pressure per APA and ADA guidance. Prolactin levels, EKG for QT concerns, and abnormal involuntary movement screening (AIMS) round out the workup depending on the agent. A 24-year-old with bipolar depression and a family history of diabetes is not a candidate for olanzapine when lurasidone is available.

Combination regimens — lithium plus quetiapine, valproate plus aripiprazole, lamotrigine plus lurasidone — are the norm rather than the exception in maintenance. RECO’s approach documents target symptoms, timelines, and taper conditions for each agent, so combinations do not accumulate by default.

Lamotrigine, valproate, and the anticonvulsant options

Lamotrigine carries the strongest evidence for maintenance in bipolar II and for patients whose predominant pole is depression. It is a poor antimanic and should not be relied on during acute mania. Titration is slow — 25 mg daily for two weeks, 50 mg for two weeks, 100 mg for one week, then 200 mg — because rapid escalation carries risk of Stevens-Johnson syndrome and toxic epidermal necrolysis. Any rash during titration is a stop-and-evaluate event.

Valproate (divalproex, extended-release) is a first-line antimanic and the preferred agent for mixed states and rapid cycling. Monitoring includes baseline and periodic LFTs, CBC with platelets, and serum levels targeting 50-125 mcg/mL. It is teratogenic and contraindicated in women of reproductive age without specific counseling and contraception planning; the neural tube defect and cognitive risk data are unambiguous.

Carbamazepine and oxcarbazepine remain second-line — useful when lithium and valproate fail, complicated by CYP450 induction and, for carbamazepine, HLA-B*1502 screening in patients of Asian ancestry. Each anticonvulsant has a defined monitoring schedule, and RECO’s practice runs each of them rather than defaulting to whichever one the clinician learned first.

What to expect on your first visit

Intake at RECO Integrated Psychiatry runs 60-90 minutes with a board-certified psychiatrist. The visit covers longitudinal mood history, family psychiatric history, prior medication trials and response, substance use, and structured screening — PHQ-9, GAD-7, MDQ, HCL-32, and ASRS where ADHD is on the differential. Collateral history from a partner or family member is requested when available, since hypomania is often invisible to the person experiencing it.

Baseline labs are ordered the same day when starting or adjusting lithium, valproate, or antipsychotics. For Miami clients, the initial evaluation is available in person at the Delray Beach office or via telepsychiatry through a HIPAA-compliant platform. Many patients complete the diagnostic visit in person and transition to telepsychiatry for medication management follow-ups every four to six weeks during stabilization, quarterly once stable.

Insurance and admissions from Miami

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Benefits verification runs before the first appointment and confirms specialist copay, deductible progress, and any prior authorization requirements — most commercial plans do not require prior auth for psychiatric evaluation and management, though they may for TMS and Spravato. Out-of-network patients receive itemized superbills for reimbursement.

Bipolar disorder treatment is coordinated with psychotherapy modalities carrying evidence in bipolar disorder — interpersonal and social rhythm therapy (IPSRT), family-focused therapy, and CBT adapted for bipolar disorder — either through RECO’s referral network or with a Miami-based therapist the patient already trusts. Coordination is written into the treatment plan, not left to the client to arrange.

Serving residents of: Brickell, Coral Gables, Coconut Grove, Aventura, Pinecrest.